Recent news on Secreflo

Repligen Announces Conference Call to Provide Update on Corporate ...  -  Apr 12, 2007
Drug Newswire (press release),In addition, we currently market two commercial products, Protein A and SecreFlo(R), which partially fund the advancement of our development pipeline while

Repligen Reports Third Quarter Fiscal Year 2007 Financial Results  -  Feb 8, 2007
PR Newswire (press release),Total revenue for the third quarter, consisting primarily of Protein A and SecreFlo(R) sales, was $3882000 compared to total revenue of $2988000 for the

Repligen Announces Conference Call of Third Quarter Fiscal Year ...  -  Feb 2, 2007
Drug Newswire (press release),In addition, we currently market two commercial products, Protein A and SecreFlo(R), which partially fund the advancement of our development pipeline while

Repligen Reports Second Quarter Fiscal Year 2007 Financial Results  Nov 2, 2006
Total revenue for the second quarter, consisting primarily of Protein A and SecreFlo® sales, was $2,865,000 compared to total revenue of $2,800,000 for the ... -Yahoo! News (press release) Repligen to Present at the Rodman & Renshaw 8th Annual Healthcare ...  Nov 3, 2006
In addition, we market two commercial products, Protein A and SecreFlo®, which partially fund the advancement of our development pipeline while supporting our ... -Yahoo! News (press release) Repligen Receives Orphan Drug Designation From The FDA For RG1068 ...  -  Nov 22, 2006
Medical News Today (press release),In addition, we currently market two commercial products, Protein A and SecreFlo(R), which partially fund the advancement of our development pipeline while

Repligen Reports Breakeven For Q1 Vs. Profit Prior Year - Quick ...  Aug 8, 2006
...to the company, the year-ago quarter results included a one time gain of $1.17 million related to a favorable settlement of the SecreFlo arbitration in May 2005 ... -Trading Markets

Repligen Announces Conference Call of First Quarter Fiscal Year ...  Aug 1, 2006
Repligen has a Specialty Pharmaceuticals business comprised of rProtein A(TM) and SecreFlo(R), the profits from which will be used to partially support the ... -PR Newswire

Repligen Reports First Quarter 2007 Financial Results  Aug 8, 2006
Total revenue for the first quarter consisting primarily of Protein A sales and SecreFlo® sales was $3,628,000 compared to total revenue of $4,239,000 for the ... -Yahoo! News

Repligen May Hit "A Home Run"  Aug 11, 2006
Repligen's Protein A, to boost antibodies, and SecreFlo, to diagnose pancreatitis and gastrinoma, a rare cancer, had sales of $12.5 million in the year ended ... -BusinessWeek



Repligen to Present at the Rodman & Renshaw Global Healthcare ...  May 9, 2006
Repligen has a Specialty Pharmaceuticals business comprised of rProtein A(TM) and SecreFlo®, the profits from which will be used to partially support the ... - Yahoo! News





Repligen Initiates Phase 2 Clinical Trial of RG2417 for Bipolar ...  Mar 9, 2006
Repligen has a Specialty Pharmaceuticals business comprised of rProtein A(TM) and SecreFlo(R), the profits from which will be used to partially support the ... - PR Newswire



Repligen Announces Conference Call for Third Quarter Fiscal Year ...  Feb 3, 2006
Repligen has a Specialty Pharmaceuticals business comprised of rProtein A(tm) and SecreFlo(r), the profits from which will be used to partially support the ... - PharmaLive.com,

Repligen Reports Third Quarter 2006 Financial Results  09 Feb 2006
...was primarily due to higher customer demand, while profit margin on product revenue was impacted favorably by the decreased royalty owed for SecreFlo(R), our ... - Finanzen.net

Repligen Announces Conference Call for Third Quarter Fiscal Year ...  Feb 2, 2006
Repligen has a Specialty Pharmaceuticals business comprised of rProtein A(TM) and SecreFlo(R), the profits from which will be used to partially support the ... - International News Service

Repligen Files Infringement Complaint Against Bristol-Myers Squibb ...  Jan 7, 2006
Repligen has a specialty pharmaceuticals business comprised of rProtein A and SecreFlo, the profits from which will be used to partially support the ... - ag-IP-news Agency

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional